The design, synthesis, and evaluation of C7 diversified bryostatin analogs reveals a hot spot for PKC affinity

Organic Letters

Volumn 10, Issue 15, 2008, Pages 3331-3334

  Wender, Paul A ^a   Verma, Vishal A ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRYOSTATIN; ISOENZYME; PROTEIN KINASE C;

ARTICLE; CELL STRAIN K 562; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG SCREENING; HUMAN; METABOLISM; SYNTHESIS;

ANTINEOPLASTIC AGENTS; BRYOSTATINS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; ISOENZYMES; K562 CELLS; MODELS, MOLECULAR; PROTEIN KINASE C;

EID: 49649093144     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol801235h     Document Type: Article

References (37)

1. Pettit, G. R.; Herald, C. L.; Doubek, D. L.; Herald, D. L.; Arnold, E.; Clardy, J. J. Am. Chem. Soc. 1982, 104, 6846-6848.
2. For current information, see http://clinicaltrials.gov.
3. Wall, N. R.; Mohammad, R. M.; Al-Katib, A. M. Leuk. Res. 1999, 23, 881-888.
4. Elgie, A. W.; Sargent, J. M.; Alton, P.; Peters, G. J.; Noordhuis, P.; Williamson, C. J.; Taylor, C. G. Leuk. Res. 1998, 22, 373-378.
5. Oz, H. S.; Hughes, W. T.; Rehg, J. E.; Thomas, E. K. Microb. Pathog. 2000, 29, 187-190.
6. For a recent clinical trial, see: Ajani, J. A.; Jiang, Y.; Faust, J.; Chang, B. B.; Ho, L.; Yao, J. C.; Rousey, S.; Dakhil, S.; Cherny, R. C.; Craig, C.; Bleyer, A Invest. New Drugs 2006, 24, 353-357.
7. Hongpaisan, J.; Alkon, D. L Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 19571-19576.
8. Etcheberrigaray, R.; Tan, M.; Dewachter, I.; Kuiperi, C.; Van der Auwera, I.; Wera, S.; Qiao, L. X.; Bank, B.; Nelson, T. J.; Kozikowski, A. P.; Van Leuven, F.; Alkon, D. L. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 11141-11146.
9. Schaufelberger, D. E.; Koleck, M. P.; Beutler, J. A.; Vatakis, A. M.; Alvarado, A. B.; Andrews, P.; Marzo, L. V.; Muschik, G. M.; Roacch, J.; Ross, J. T.; Lebherz, W. B.; Reeves, M. P.; Eberwein, R. M.; Rodgers, L. L.; Testerman, R. P.; Snader, K. M.; Forenza, S. J. Nat. Prod. 1991, 54, 1265-1270.
10. (a) Wender, P. A.; DeBrabander, J.; Harran, P. G.; Jimenez, J. M.; Koehler, M. F. T.; Lippa, B.; Park, C. M.; Siedenbiedel, C.; Pettit, G. R Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 6624-6629.
11. (b) Kortmansky, J.; Schwartz, G. K. Cancer Invest. 2003, 21, 924-936.
12. (a) Evans, D. A.; Carter, P. H.; Carreira, E. M.; Charette, A. B.; Prunet, J. A.; Lautens, M. J. Am. Chem. Soc. 1999, 121, 7540-7552.
13. (b) Kageyama, M.; Tamura, T.; Nantz, M. H.; Roberts, J. C.; Somfai, P.; Whritenour, D. C.; Masamune, S. J. Am. Chem. Soc. 1990, 112, 7407-7408.
14. (c) Ohmori, K.; Ogawa, Y.; Obitsu, T.; Ishikawa, Y.; Nishiyama, S.; Yamamura, S. Angew. Chem., Int. Ed. 2000, 39, 2290-2294.
15. (a) Lopanik, N.; Lindquist, N.; Targett, N. Oecologia 2004, 139, 131-139.
16. (b) Sudek, S.; Lopanik, N. B.; Waggoner, L. E.; Hildebrand, M.; Anderson, C.; Liu, H. B.; Patel, A.; Sherman, D. H.; Haygood, M. G. J. Nat. Prod. 2007, 70, 67-74.
17. (a) Wender, P. A.; Verma, V. A.; Paxton, T. J.; Pillow, T. H. Acc. Chem. Res. 2008, 41, 40-49.
18. (b) Wender, P. A.; Koehler, K. F.; Sharkey, N. A.; Dellaquila, M. L.; Blumberg, P. M Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 4214-4218.
19. (a) Wender, P. A.; Baryza, J. L.; Bennett, C. E.; Bi, F. C.; Brenner, S. E.; Clarke, M. O.; Horan, J. C.; Kan, C.; Lacôte, E.; Lippa, B. S.; Nell, P. G.; Turner, T. M. J. Am. Chem. Soc. 2002, 124, 13648-13649.
20. For other recent analog work, see: (b) Wender, P. A.; DeChristopher, B. A.; Schrier, A. J. J. Am. Chem. Soc. 2008, 130, 6658-6659.
21. (c) Keck, G. E.; Kraft, M. B.; Truong, A. P.; Li, W.; Sanchez, C. C.; Kedei, N.; Lewin, N. E.; Blumberg, P. M. J. Am. Chem. Soc. 2008, 130, 6660-6661.
22. (d) Wender, P. A.; Horan, J. C.; Verma, V. A Org. Lett. 2006, 8, 5299-5302, and references therein.
23. (e) For a review of our bryostatin analog program, see: Wender, P. A.; Baryza, J. L.; Hilinski, M. K.; Horan, J. C.; Kan, C.; Verma, V. A. Beyond Natural Products: Synthetic Analogues of Bryostatin 1 In Drug Discovery Research: New Frontiers in the Post-Genomic Era; Huang, Z., Ed.; Wiley-VCH: Hoboken, NJ, 2007; pp 127-162.
24. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S Science 2002, 298, 1912-1934.
25. Wender, P. A.; Baryza, J. L.; Brenner, S. E.; Clarke, M. O.; Craske, M. L.; Horan, J. C.; Meyer, T. Curr. Drug Discov. Tech. 2004, 1, 1-11.
26. Dries, D. R.; Gallegos, L. L.; Newton, A. C. J. Biol. Chem. 2007, 282, 826-830.
27. (a) Keck, G. R.; Covel, J. A.; Schiff, T.; Yu, T. Org. Lett. 2002, 4, 1189-1192.
28. (b) Mekhalfia, A.; Markó, I. E.; Adams, H. Tetrahedron Lett. 1991, 32, 4783-4786.
29. Item 49.60 from Jülich Chiral Solutions (www.codexis.com) for 33 euros/g.
30. Available in one step: (a) Clive, D. L. J.; Paul, C. C.; Wang, Z. J. Org. Chem. 1997, 62, 7028-7032.
31. (a) Yu, C. M.; Lee, J. Y.; So, B.; Hong, J. Angew. Chem., Int. Ed 2002, 41, 161-163.
32. (b) Kurosu, M.; Lorca, M. Tetrahedron Lett. 2002, 43, 1765-1769.
33. (a) Yu, C. M.; Choi, H. S.; Yoon, S. K.; Jung, W. H. Synlett 1997, 889-890.
34. (b) Yu, C. M.; Choi, H. S.; Jung, W. H.; Kim, H. J.; Shin, J. Chem. Commun. 1997, 761-762.
35. (a) Wender, P. A.; Verma, V. A Org. Lett. 2006, 8, 1893-1896.
36. For a related application, see: (b) Smith, A. B.; Razler, T. M.; Meis, R. M.; Pettit, G. R. Org. Lett. 2006, 8, 797-799.
37. Wender, P. A.; Irie, K.; Miller, B. L Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 239-243.